Senti Biosciences (SNTI) Registration filing summary

Management team and governance

• CEO is Timothy Lu, M.D., Ph.D., with principal executive office in South San Francisco, CA.

• Board includes Jay Cross (CFO), Bryan Baum, James Collins, Ph.D., Brenda Cooperstone, M.D., Feng Hsiung, Edward Mathers, Frances D. Schulz, and Donald Tang.

• Registration statement signed by all directors and principal officers on September 22, 2026.

Offering details and pricing

• Registration statement filed as Form S-3 for a proposed public offering to be made from time to time after effectiveness.

• Securities may be offered on a delayed or continuous basis under Rule 415.

• Filing is an amendment to update auditor consent; no changes to the remainder of the registration statement.

Underwriters and syndicate

• Legal counsel includes Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.

• KPMG LLP serves as the independent registered public accounting firm.